Researchers have created the largest collection of patient stem cell models of multiple sclerosis, identifying unique ways in which glia contribute to the disease. The study suggests that glial cells from MS patients have intrinsic hallmarks of disease, independent of immune system influences.
The NYSCF – Robertson Stem Cell Investigator Awards support promising early career scientists with cutting-edge research, providing $1.5 million over five years for seed funding. The latest cohort includes three talented researchers who will join the thirteenth class of NYSCF – Robertson Stem Cell Investigators.
The New York Stem Cell Foundation (NYSCF) has selected six early-career researchers to join its prestigious investigator program, which provides $1.5 million in funding over five years. The award aims to accelerate treatments and cures through cutting-edge research.
Researchers developed an AI-driven image analysis pipeline that identified novel cellular hallmarks of Parkinson's disease from images of over a million skin cells. The platform can distinguish between patient cells and healthy controls, revealing new signatures for potential therapeutic targets.
The New York Stem Cell Foundation (NYSCF) has announced the 2020 class of NYSCF - Robertson Investigators, recognizing six outstanding stem cell researchers and neuroscientists. The program provides critical seed funding to support cutting-edge research with the potential to accelerate treatments and cures.
A study by NYSCF Research Institute creates human stem-cell-derived astrocytes that become toxic to neurons in disease-like environments. This phenomenon could lead to effective treatments for neurodegenerative diseases such as multiple sclerosis, Parkinson's, and Alzheimer's.
The New York Stem Cell Foundation (NYSCF) has announced the 2019 class of NYSCF - Robertson Investigators, including Ya-Chieh Hsu, Evangelos Kiskinis, Florian Merkle, Nicholas Bellono, Lauren O'Connell and six others. The award provides $1.5 million over five years to outstanding young scientists.
A four-year study of over 500 research institutions found that promotion, recruitment, and retention of women to senior roles are lacking in STEM. Despite efforts by some institutions to implement supportive policies, the report suggests a persistent need for action to achieve gender equity.
Researchers at NYSCF identified two growth media types that support effective expansion of mesenchymal progenitor cells for bone treatment and repair. MP cells have promise in treating blood, heart, and immune diseases as well as repairing damaged bone and cartilage.
The New York Stem Cell Foundation has selected six promising researchers for its 2018 class of NYSCF-Robertson Investigators. These scientists will receive $1.5 million in funding to pursue high-risk, high-reward research projects in stem cell biology and neuroscience.
Researchers have developed a new procedure to generate human brain 'organoids' capable of myelination, modeling the brain's structure and function more closely than ever. This breakthrough could lead to better understanding and treatment of neurological diseases such as multiple sclerosis and Pelizaeus-Merzbacher disease.
The NYSCF Research Institute has developed a novel bioengineering technique called Segmental Additive Tissue Engineering (SATE), allowing for the creation of large-scale, personalized bone grafts. This technology overcomes limitations of current treatments, such as immune rejection and limited size and shape options.
The New York Stem Cell Foundation (NYSCF) has selected six promising researchers and neuroscientists to join the NYSCF - Robertson Investigators program, providing critical seed funding of $1.5 million over five years. The program supports high-risk/high-reward research that aims to accelerate treatments and cures for various diseases.
Dr. Paul Tesar receives the 2017 NYSCF Robertson Stem Cell Prize for his pioneering work on pluripotent epiblast stem cells, which holds promise for treating neurological disorders like multiple sclerosis and pediatric leukodystrophies.
Scientists have developed a high-throughput protocol to derive human microglia from stem cells, which can be used to investigate the role of microglia in neurological disorders. This new method enables researchers to generate microglia from individual patients' samples and advance complex disease modeling in a dish.
The National Stem Cell Foundation has funded a grant to study how astrocytes can be manipulated to halt or prevent neurodegeneration in diseases like MS and Parkinson's. The researchers aim to advance understanding of cell cross-talk in the central nervous system.
Scientists at NYSCF Research Institute discovered strategies to prevent mitochondrial mixtures, leading to effective mitochondrial replacement. Egg freezing enables doctors to avoid synchronized ovulation between patient and donor, allowing for safer treatment of mitochondrial diseases.
The New York Stem Cell Foundation has awarded $7.5 million to five researchers through the NYSCF -- Robertson Investigator Program, supporting innovative work in stem cell biology and neuroscience. The recipients aim to advance our understanding of cellular processes and develop new treatments for diseases.
Franziska Michor is awarded the NYSCF -- Robertson Stem Cell Prize for her interdisciplinary research on cancer genesis, using mathematical models to understand cancer evolution. Her work simulates drug treatment regimens and has been tested in clinical trials for non-small-cell lung cancer and brain tumors.
Researchers designed a revolutionary high-throughput robotic platform to automate the process of generating patient-specific stem cells, reducing variability and increasing scale. This technology allows for 'clinical trials in a dish' and can identify potential drug metabolism and toxicity issues in human cells before clinical trials.
The New York Stem Cell Foundation (NYSCF) has proposed seven strategies to advance women in science, engineering, and medicine, including flexible family care spending and recruiting gender-balanced review committees. The initiatives aim to promote gender equality and break down barriers to advancement in these fields.
Researchers at NYSCF found that SCNT-derived cells and IPS cells share similar genetic profiles, suggesting both methods are effective in generating stem cells. The study's findings imply that further investigation is needed to determine the suitability of each method for treating chronic diseases.
Researchers created a cellular model of Parkinson's disease using human stem cells from identical twins with the disease. The study found that dopamine-producing neurons had reduced activity and higher levels of α-synuclein protein, which can be targeted for therapy.
The New York Stem Cell Foundation has launched the largest-ever stem cell repository, offering over 600 induced pluripotent stem (iPS) cell lines from diverse human subjects. The repository provides a vast resource for scientists to study various diseases, including type 1 diabetes, Parkinson's disease, and multiple sclerosis.
The New York Stem Cell Foundation has awarded $9 million to six promising scientists, including three stem cell researchers and three neuroscience researchers. The awards will enable them to expand their laboratories and train other scientists.
Researchers at The New York Stem Cell Foundation have developed a new protocol to induce pluripotent stem cells into oligodendrocytes, the myelin-forming cells implicated in multiple sclerosis. This accelerated approach cuts production time almost in half, enabling researchers to study disease progression and develop potential treatments.
The New York Stem Cell Foundation (NYSCF) and the eagle-i Network will make NYSCF iPS cell lines and related information available on a user-friendly, web-based, searchable database. This database will help scientists find valuable resources, enabling collaboration and accelerating research.
Researchers at NYSCF and Columbia University Medical Center have successfully created the first disease-specific human embryonic stem cell line using somatic cell nuclear transfer (SCNT). The achievement marks a major step towards developing personalized cell therapies for life-threatening diseases like type 1 diabetes. By reprogrammin...
Scientists have identified fourteen genes that may be implicated in Alzheimer's disease and one gene that shows inflammation plays a crucial role in the brain of Alzheimer's patients. The study provides new insight into the cause of the disease, offering potential targets for drug discovery.
Researchers at NYSCF and Columbia University Medical Center successfully generated iPS cells from frozen brain tissue, allowing for the study of Alzheimer's disease at a cellular level. The new stem cell lines will enable drug testing on cells from patients with confirmed diagnoses.
Researchers used induced pluripotent stem cells from patients with Wolfram syndrome to model beta-cell failure. They found that protein-folding stress caused cells to fail and discovered a chemical, 4-phenyl butyric acid, that relieves this stress, potentially leading to new treatments.
The New York Stem Cell Foundation has awarded $10.5 million to seven researchers to advance their studies in stem cell biology and neuroscience. The new NYSCF – Robertson Investigators will receive funding over five years to expand their laboratories and train other scientists.
NYSCF and PPMI collaborate to develop stem cell lines from patients, enabling researchers to study Parkinson's disease progression. The partnership aims to identify biomarkers and accelerate treatment development.
Researchers from NYSCF and Columbia University have generated patient-specific beta cells using skin cells from MODY patients. These cells accurately reflect the features of maturity-onset diabetes of the young (MODY) and can be used to develop new therapies for the disease. The study's findings demonstrate a critical proof-of-principl...
Researchers at NYSCF's Research Institute created patient-specific bone substitutes from skin cells to repair large bone defects. The new method uses induced pluripotent stem (iPS) cells, which can become any body cell type, and overcomes previous limitations of bone formation.
New York Stem Cell Foundation researchers have developed a quantitative protocol to consistently harvest early-reprogrammed cells, resulting in standardized iPS cell lines. This method enables the derivation of 228 individual iPS cell lines, which can be compared to one another for use in drug screens and cell therapies.
Researchers at the New York Stem Cell Foundation have developed a 3D stem cell culture technique to study Alzheimer's disease. This technique enables the creation of neuron aggregates that can be used to model and study diseases such as Alzheimer's and Parkinson's.
Researchers from NYSCF and CUMC developed a technique to transfer human egg cells' nuclei, eliminating the inheritance of mitochondrial diseases. This method demonstrates permanent elimination of mitochondrial DNA, preventing future generations from developing these devastating diseases.
The New York Stem Cell Foundation has announced funding of $9 million to six new investigators conducting innovative stem cell and neuroscience research. The award will support these researchers as they establish their own laboratories and expand their work.
A team of scientists at the New York Stem Cell Foundation developed a cell-based model of Alzheimer's disease by reprogramming skin cells from patients into brain cells that are affected in Alzheimer's. The model recapitulates the features and functions of patient suffering from Alzheimer's, providing a critical tool for future researc...
Researchers at NYSCF have successfully grown compact bone tissue using human embryonic stem cells, which can be used to repair and replace damaged bone in patients. The breakthrough could lead to personalized bone grafts that avoid immune rejection.
Professor Peter J. Coffey's pioneering stem cell research aims to replace damaged retinal pigment epithelium cells in Age-Related Macular Degeneration. Clinical trials using his therapy are expected to begin in 2012, offering hope for preventing blindness and restoring sight.
Researchers created functional neurons from human skin cells using four proteins, bypassing the creation of induced pluripotent stem cells. This advancement enables the study of neural diseases and development of more effective treatments and cures.
Dr. Paul Tesar's research enhances understanding of pluriportent stem cells used to study debilitating diseases. His findings have potential to prevent or repair damage caused by disease, aging, and injury.
A team of researchers led by Dr. Christopher Fasano successfully derived floor plate tissue from human embryonic stem cells, a crucial signaling center in brain development. This achievement paves the way for better understanding of neurodegenerative diseases like Parkinson's.
A study led by NYSCF Fellow Daylon James has generated a human embryonic stem cell line to measure and boost endothelial cell production, establishing a standard methodology for producing functional endothelial cells from hESCs. The cells can now be used for pre-clinical assessment of vascular disease in large animal models.
Dr. Kevin Eggan's breakthrough discovery marks the first time scientists have replicated specific human cells affected by ALS in a laboratory setting. The New York Stem Cell Foundation funded his work and will continue to support him.